The presence of fat-enlarged axillary lymph nodes on mammography screening exams is associated with a fourfold higher risk of type 2 diabetes and a 2.6-fold higher risk for cardiovascular disease, according to new research presented at the ARRS Annual Meeting.
Emerging research suggests the detection of fat-enlarged axillary lymph nodes on screening mammography exams may be associated with significantly higher risks of type 2 diabetes (T2DM), cardiovascular disease (CVD), and hypertension (HTN).
In a retrospective study, which garnered Summa Cum Laude honors at the 2024 American Roentgen Ray Society (ARRS) Annual Meeting in Boston, researchers reviewed bilateral mediolateral oblique views from mammography exams for 1,216 women who had cardiovascular risk factors within one year of the mammogram but no known coronary artery disease (CAD) at the time of the mammography screening. The study authors measured the largest visible axillary lymph node and also determined if the patients had any major adverse cardiovascular events (MACEs) within 10 years after the index mammogram.
The researchers found that 19.1 percent of the cohort had fat-enlarged axillary lymph nodes (greater than 20 mm in length) due to an expanded fatty hilium. For these patients, the study authors noted a fourfold higher risk for T2DM, a 2.6-fold higher risk of CVD, and a 2.5-fold higher risk of HTN.
“Fat-enlarged axillary lymph nodes visualized on screening mammography may increase the ability to identify women who would benefit from CVD risk reduction strategies and more intensive risk assessment with coronary artery CT,” suggested lead study author Jessica Rubino, M.D., who is affiliated with the Dartmouth Hitchcock Medical Center in Lebanon, N.H., and colleagues.
The researchers noted that axillary lymph nodes were visible on 907 of the 1216 mammography exams reviewed in the study (74.6 percent). Emphasizing the wide eligibility for screening mammography for over 75 percent of women in the United States, the study authors emphasized that obtaining cardiovascular risk data from mammograms could have a significant impact in reducing mortality from CVD, the leading cause of death in women.
“If validated in larger studies, incorporating fat-enlarged nodes into CVD risk models has the potential to improve CVD risk stratification without additional cost or additional testing,” posited Rubino and colleagues.
Reference
1. Rubino J, Austin-Strohbehn J, Wang Q, et al. Fat-enlarged axillary lymph nodes on screening mammograms predict cardiometabolic disease and cardiovascular disease risk. Presented at the 2024 American Roentgen Ray Society (ARRS) Annual Meeting in Boston, May 5-9, Boston. Available at: https://apps.arrs.org/MeetingPortal24/ . Accessed May 5, 2024.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.